IKT Company Profile and Key Details
Inhibikase Therapeutics, Inc.
IKT Stock Price Chart
Stock Price Today
Inhibikase Therapeutics, Inc. (IKT) stock declined over -0.36%, trading at $2.80 on NASDAQ, down from the previous close of $2.81. The stock opened at $2.80, fluctuating between $2.73 and $2.84 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
Company Information
| Employees | 8 |
| Beta | 1.12 |
| Sales or Revenue | $260.50K |
| 5Y Sales Change% | -0.984% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Inhibikase Therapeutics, Inc. (NASDAQ: IKT) stock price is $2.80 in the last trading session. During the trading session, IKT stock reached the peak price of $2.84 while $2.73 was the lowest point it dropped to. The percentage change in IKT stock occurred in the recent session was -0.36% while the dollar amount for the price change in IKT stock was -$0.01.
The NASDAQ listed IKT is part of Biotechnology industry that operates in the broader Healthcare sector. Inhibikase Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Milton H. Werner Ph.D.
Chief Executive Officer, Pres & Director
Mr. Joseph Frattaroli CPA
Chief Financial Officer
Dr. Roger Rush
Head of Preclinical Research
Dr. Surendra Singh
Head of Chemistry, Manufacturing & Controls
Dan Williams
Controller
Dr. Charles Warren Olanow B.Sc., F.R.C.P.C., M.D.
Chief Executive Officer of Clintrex Research Corporation & Member of Scientific Advisory Board
IKT's closing price is 150% higher than its 52-week low of $1.12 where as its distance from 52-week high of $4.20 is -33.33%.
Number of IKT employees currently stands at 8.
Official Website of IKT is: https://www.inhibikase.com
IKT could be contacted at phone 678 392 3419 and can also be accessed through its website. IKT operates from 3350 Riverwood Parkway SE, Atlanta, GA 30339, United States.
IKT stock volume for the day was 79.66K shares. The average number of IKT shares traded daily for last 3 months was 321.22K.
The market value of IKT currently stands at $194.21M with its latest stock price at $2.80 and 69.36M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com